No Data
No Data
Express News | Point72 Asset Management, L.p. Reports 5.9% Passive Stake in Dianthus Therapeutics as of April 10 - SEC Filing
12 Health Care Stocks Moving In Friday's Pre-Market Session
We Think Dianthus Therapeutics (NASDAQ:DNTH) Can Afford To Drive Business Growth
A Quick Look at Today's Ratings for Dianthus Therapeutics(DNTH.US), With a Forecast Between $40 to $52
Dianthus Therapeutics Reports 2024 Financial Results and Clinical Progress
Dianthus Therapeutics Shares Fall as Q4 Results Miss Expectations